bluebird bio, Inc., based in Somerville, Massachusetts, is a biotechnology company that develops gene therapies for severe genetic disorders.[1]
The company's only - in the European Union (EU) - approved drug is betibeglogene autotemcel (Zynteglo), which treats transfusion-dependent beta thalassemia (TDT), a rare genetic blood disorder, and has been approved for use by the European Medicines Agency.[2] The company has been criticized for the $1.8 million cost of the drug, which is the second most expensive drug in the world.[3][4][5]
The company is developing LentiGlobin[6] gene therapy for the treatment of sickle cell disease and cerebral adrenoleukodystrophy. It is also developing T cell product candidates to treat acute myeloid leukemia, Merkel-cell carcinoma, diffuse large B-cell lymphoma, and MAGEA4 solid tumors.[1]
^ abc"bluebird bio, Inc. 2021 Annual Report (Form 10-K)". U.S. Securities and Exchange Commission. March 4, 2022.
^"Zynteglo". European Medicines Agency.
^Lovelace, Berkeley (June 14, 2019). "Bluebird Bio CEO defends $1.8 million price for gene therapy — 'It's really thinking about it differently'". CNBC.
^LaMattina, John (19 June 2019). "What Bluebird Bio Gets Wrong In Pricing For Its $1.8 Million Drug". Forbes.
^Kolata, Gina (September 11, 2017). "New Gene-Therapy Treatments Will Carry Whopping Price Tags". The New York Times.
^"Anemia Treatment Drugs: 2019 Global Market Study; Analyzed by Type of Anemia, Type of Drug, and Geography". GlobeNewswire. 2019-04-26. Retrieved 2023-08-02.
bluebirdbio, Inc., based in Somerville, Massachusetts, is a biotechnology company that develops gene therapies for severe genetic disorders. The company's...
used to treat cerebral adrenoleukodystrophy (CALD). It was developed by Bluebirdbio and was given breakthrough therapy designation by the U.S. Food and Drug...
therapy for the treatment for beta thalassemia. It was developed by BluebirdBio and was given breakthrough therapy designation by the US Food and Drug...
advanced therapy designations. The FDA granted approval of Lyfgenia to BluebirdBio Inc. The cost effectiveness threshold of the therapy is estimated to...
PMID 22388279. Liu, Angus (September 19, 2022). "A $3M gene therapy: Bluebirdbio breaks its own pricing record with FDA approval of Skysona". Fierce Pharma...
with bluebirdbio in cancer immunotherapy. In 2017, Medigene disposed of the US rights for Veregen and expanded its partnership with bluebirdbio in 2018...
gene therapy treatment for use with beta thalassemia. The manufacturer Bluebirdbio charges $2.8 million in the United States for its one-time treatment...
aggressive Non-Hodgkin's Lymphoma has been treated. In June, Kite Pharma and bluebirdbio, Inc. announced they have entered into a collaboration agreement to co-develop...
S. Food and Drug Administration Approves Bristol Myers Squibb's and bluebirdbio's Abecma (idecabtagene vicleucel), the First Anti-BCMA CAR T Cell Therapy...
2017-12-12. Orelli, Brian. "Better Buy: Bellicum Pharmaceuticals, Inc. vs. bluebirdbio". The Motley Fool. Retrieved 2017-12-12. "AP32788 is ARIAD's most recent...
acquired by Pfizer AZD – AstraZeneca BAN – BioArctic Neuroscience AB, Sweden BAY – Bayer AG BB – BluebirdBio BCX – Laboratoires Biocodex BI - Boehringer...
combined immunodeficiency was performed by Cavazzana in collaboration with bluebirdbio in 2000. When it was established that two of the boys developed leukaemia...
Fireman Sam Pingu Thomas & Friends Business units Corporate acquisitions Bluebird Fuhu Gullane Entertainment Lyrick Studios HIT Entertainment Ideal J. W...
Century Fox film Sun Valley Serenade. The Glenn Miller recording, RCA Bluebird B-11230-B, became the No. 1 song across the United States on December 7...
1939 at the RCA Victor Studios in New York City and released on the RCA Bluebird label. It was a Top Ten hit on the U.S. pop charts in 1939, reaching number...
wrote a composition entitled "HaabiaTupi." In 2002, Elias signed with RCA/Bluebird, which issued Kissed by Nature. Dreamer was released in 2004 and received...
Global Information
US$3.66 million (2021)
US$−819 million (2021)